navig co-pilot sell stake
view posit sell major navihealth
busi privat equiti partner believ navihealth
manag team pe partner deliv focu asset
potenti drive faster growth also view posit
allow medic segment manag focu attent
challeng busi within segment
partnership growth cardin announc today sell
navihealth busi cd tax proce
impli total valu busi cardin decid
sell major stake busi core distribut
busi allow navihealth leadership pe partner focu
grow busi deal expect close
acquir cardin acquir share navihealth
busi aug indic valu busi
cardin subsequ spent acquisit within
navihealth execut put right minor holder
navihealth transact rais cardin
ownership indic total invest
ownership navihealth
financi impact cardin deconsolid navihealth result
financi report report contribut ownership
stake incom estim busi
ebitda base multipl valuat busi
indic drag pre-tax incom stake sale
neg ep drag earn could smaller
proce transact direct share repurchas
accret acquisit lower ep estim
drag transact partial off-set
updat model share repurchas activ
maintain sector perform maintain sector perform rate
share lower pt lower ep estim
price target reflect price-to-earnings multipl appli ep estim
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
cardin health one three larg drug wholesal
unit state believ share like
multipl range-bound investor get visibl
gener drug price bottom oper
earn growth resum compani
pressur last month gener drug price
deflat increas wholesal competit higher-margin
independ custom slowdown brand drug price
increas weigh result expect
backdrop improv next twelv month end
believ investor expect estim
compani core drug distribut segment bottom
could continu disappoint
estim cardin gener
profit core us drug distribut busi sale
gener drug past two year cardin seen
price gener drug deflat high singl digit mid-teen
percentag rate profit dollar contribut fall
slightli lower rate cardin grow profit gener
drug need volum growth new introduct off-set
impact drug price deflat believ
possibl gener deflat continu high singl digit
pace higher thu current environ persist
upsid risk rate includ stabil drug
price environ could caus earn estim
stabil like drive multipl expans close
outperform expect drive posit earn
gener market potenti client loss
wholesal sell side price compress
larger pharmaci custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount year averag forward trade multipl
share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep upsid scenario
ep better ep growth could driven
success medic devic strategi increas volum across
brand gener drug de-lever balanc sheet
level gener price deflat forward
multipl repres high end normal trade
rang drug wholes space multipl
like get neg share
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower expect ep could
driven hiccup implement medic devic
strategi wors expect price environ lower
expect brand gener volum forward
multipl like get posit share
price target share equal ep estim use
multipl reflect slight discount year averag forward trade multipl
share reflect challeng medic segment price target support
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
cah medic surgic busi could also outperform expect drive posit
earn surpris downsid risk includ acceler drug price deterior
gener market potenti client loss wholesal sell side
price compress larger pharmaci custom gpo
healthcar servic product compani offer solut health
system pharmaci healthcar provid compani oper
medic segment busi distributor
brand gener drug specialti drug over-the-counter healthcar product
segment also provid specialti pharmaci servic china joint ventur
call red oak sourc sourc gener pharmaceut
medic busi distributor nation brand medic surgic
laboratori product healthcar provid patient home segment addit
provid profession servic healthcar provid
good sold
revenu
impair charg net
litig credit net
revenu
adj profit tax
profit tax
weight average number share
